secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2023-07-06T23:59:59+00:00
Accession:  0000899923-23-000047
Event type: debt
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics establishes new $90M asset-based credit facility expandable to $115M
--------------------------------------------------------------------------------

- New $90M ABL Facility with option to increase by $25M to $115M; matures June 30, 2026.
- Lenders: JPMorgan Chase (admin agent), Wells Fargo, Bank of America; secured by substantially all assets.
- Proceeds for working capital, general corporate purposes, and refinancing existing debt.
- Interest rate options: ABR plus 1.00%-1.50% or Term SOFR plus 2.00%-2.50% based on unused availability.
- Replaces prior credit facility; CEO Paul Diaz cites added financial flexibility for growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000047/0000899923-23-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000047/mygn-20230630.htm
  HTML page:      https://secwatch.observer/filing/0000899923-23-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer